IL137489A0 - Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway - Google Patents

Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway

Info

Publication number
IL137489A0
IL137489A0 IL13748999A IL13748999A IL137489A0 IL 137489 A0 IL137489 A0 IL 137489A0 IL 13748999 A IL13748999 A IL 13748999A IL 13748999 A IL13748999 A IL 13748999A IL 137489 A0 IL137489 A0 IL 137489A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
containing inhibitors
lymphotoxin
pathway
Prior art date
Application number
IL13748999A
Other languages
English (en)
Original Assignee
Univ New York
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Biogen Inc filed Critical Univ New York
Publication of IL137489A0 publication Critical patent/IL137489A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13748999A 1998-01-30 1999-01-29 Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway IL137489A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (1)

Publication Number Publication Date
IL137489A0 true IL137489A0 (en) 2001-07-24

Family

ID=26754147

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13748999A IL137489A0 (en) 1998-01-30 1999-01-29 Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
IL137489A IL137489A (en) 1998-01-30 2000-07-25 Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137489A IL137489A (en) 1998-01-30 2000-07-25 Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway

Country Status (25)

Country Link
EP (1) EP1051187B9 (ja)
JP (2) JP4713733B2 (ja)
KR (1) KR100622960B1 (ja)
CN (1) CN1287853C (ja)
AT (1) ATE253930T1 (ja)
AU (1) AU752710B2 (ja)
BR (1) BR9908214A (ja)
CA (1) CA2319698A1 (ja)
CZ (1) CZ301026B6 (ja)
DE (1) DE69912743T2 (ja)
DK (1) DK1051187T3 (ja)
EA (1) EA003862B1 (ja)
EE (1) EE05235B1 (ja)
ES (1) ES2211035T3 (ja)
HK (1) HK1029944A1 (ja)
HU (1) HU226044B1 (ja)
IL (2) IL137489A0 (ja)
IS (1) IS2254B (ja)
NO (1) NO328116B1 (ja)
NZ (1) NZ506529A (ja)
PL (1) PL203279B1 (ja)
PT (1) PT1051187E (ja)
SK (1) SK285725B6 (ja)
TR (2) TR200002203T2 (ja)
WO (1) WO1999038525A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0012006A (pt) * 1999-06-28 2002-03-12 Basf Ag Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
CA2425809A1 (en) 2000-10-13 2002-04-18 Biogen, Inc. Humanized anti-lt-.beta.-r antibodies
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
BR0308250A (pt) 2002-03-04 2005-01-11 Aton Pharma Inc Métodos de indução de diferenciação terminal
EP1539793A4 (en) 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
NZ538509A (en) * 2002-08-14 2007-11-30 Univ Erasmus Medical Ct Use of murine genomic regions identified to be involved in tumor development for the development of anit-cancer drugs and diagnosis of cancer
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
IS5570A (is) 2000-07-21
ES2211035T3 (es) 2004-07-01
JP2002501902A (ja) 2002-01-22
IL137489A (en) 2010-05-31
EE05235B1 (et) 2009-12-15
KR20010040497A (ko) 2001-05-15
WO1999038525A1 (en) 1999-08-05
AU2348899A (en) 1999-08-16
JP4713733B2 (ja) 2011-06-29
DK1051187T3 (da) 2004-03-08
PT1051187E (pt) 2004-03-31
HU226044B1 (en) 2008-03-28
JP2010235621A (ja) 2010-10-21
TR200101693T2 (tr) 2002-06-21
CN1287853C (zh) 2006-12-06
ATE253930T1 (de) 2003-11-15
EP1051187B9 (en) 2004-08-11
BR9908214A (pt) 2000-11-28
CZ301026B6 (cs) 2009-10-14
HUP0102363A2 (hu) 2001-10-28
NO20003848L (no) 2000-10-02
DE69912743T2 (de) 2004-09-23
SK11302000A3 (sk) 2001-01-18
IS2254B (is) 2007-06-15
CA2319698A1 (en) 1999-08-05
EE200000446A (et) 2001-08-15
CN1289252A (zh) 2001-03-28
SK285725B6 (sk) 2007-07-06
EP1051187A1 (en) 2000-11-15
EA003862B1 (ru) 2003-10-30
KR100622960B1 (ko) 2006-09-12
NZ506529A (en) 2002-12-20
NO328116B1 (no) 2009-12-14
PL342063A1 (en) 2001-05-21
EP1051187B1 (en) 2003-11-12
TR200002203T2 (tr) 2000-12-21
AU752710B2 (en) 2002-09-26
CZ20002751A3 (cs) 2000-12-13
PL203279B1 (pl) 2009-09-30
HUP0102363A3 (en) 2004-04-28
DE69912743D1 (de) 2003-12-18
EA200000798A1 (ru) 2001-02-26
HK1029944A1 (en) 2001-04-20
NO20003848D0 (no) 2000-07-27

Similar Documents

Publication Publication Date Title
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TW200510375A (en) New compounds
MXPA03004832A (es) Compuestos y sus usos.
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
AP9901478A0 (en) Compounds for the treatment of ischemia.
IL139862A0 (en) Thiazolidine or pyrrolidine derivatives as dipeptidyl peptidase iv effectors and pharmaceutical compositions containing the same
IL151313A0 (en) Lipase containing pharmaceutical compositions
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
SE9802208D0 (sv) Novel compounds
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
YU13301A (sh) Muskarinski agonisti i antagonisti
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
GB9907571D0 (en) Compounds
SE9802209D0 (sv) Novel compounds
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
EP0758312A4 (en) SUBSTITUTED CONDENSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS
MY133682A (en) Substituted pyrroles
IL139144A0 (en) Mycobacterial inhibitors
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
DE69824410D1 (en) Antithrombosemittel